Method of purifying endothelial cell growth factors using immobi

Details Method of purifying endothelial cell growth factors using immobi Method of purifying endothelial cell growth factors using immobi

1986-04-07

1989-11-21

Weimar, Elizabeth C.

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Enzymatic production of a protein or polypeptide

530413, 530416, 210660, C12P 2100, C07K 320

Patent

active

048822752

ABSTRACT:
Endothelial cell growth factor (ECG) from various sources possesses a strong and specific affinity for heparin. This strong affinity of ECG for heaprin enables removal of undesired impurities from a mixture comprising ECG by: (a) contacting immobilized heparin with the mixture to form a heparin-ECG complex; (b) separating uncomplexed mixture from the complex; and (c) contacting the complex with a salt solution of a salt concentration and pH effective to separate the ECG from the heparin. The resulting purified ECG (or fragment thereof) is useful in therapeutics and as an additive for cell culturing. The purified ECG is also useful to raise antibodies that are used in therapeutics and in ECG immunoassays.

REFERENCES:
Olander et al.; In Vitro 18 (2): 99-107, Feb. 1982.
Gross et al.; Proc. Nat'l. Acad. Sci, 80 (9): 2623-2627, May 1983.
Shing et al., (6/1983) Abstracts, 74th Annual Meeting of Am. Soc. of Biol. Chemists, No. 418, p. 1829.
Shing et al., (11/1983) Abstracts, 23'rd Annual Meeting of the Am. Soc. for Cell Biol. No. 1488, p. 395a.
Clemmons et al., (3/1983) Proc. Nat'l. Acad. Sci. 80, 1641-1645.
Sullivan and Klagsbrun (2/1985) J. Biolog. Chem. 260(4):2399-2403.
D'Amore and Klagsbrun (10/1984) J. Cell. Biol. 99:1545-1549.
Lobb et al., J. Biol. Chem. 261(4):1924 (2/1986).
Shing et al., (3/1984) Science 223:1296-1299.
Maciag et al., (8/1984) Science 225:932-934.
Conn and Hatcher (10/1984) Biochem. and Biophys. Res. Comm. 124(1):262-268.
Lobb and Fett (12/1984) Biochem. 23:295.
Gospodarowicz et al., (11/1984) Proc. Nat'l. Acad. Sci. 81:6963-6967.
Gospodarowicz et al., (4/1985) Biochem. and Biophys. Res. Comm. 128(2):554-562.
Klagsbrun and Shing (2/1985) Proc. Nat'l. Acad. Sci. 82:805-809.
Bohen et al., (8/1984) Proc. Nat'l. Acad. Sci. 81:5364-5368.
Bohlen et al., (1/1985) J. Cell. Biochem. (Supp) 9a:133.
Esch et al., (10/1985) Proc. Nat'l. Acad. Sci. 82:6507-6511.
Gimenez-Gallego et al., (12/1985) Science 230 (4732):1385-1389.
Bohlen et al., (6/1985) FEBS 185 (1)177-181.
Shing et al., (1985) J. Cell. Biochem. 29:275-287.
Maciag et al., (5/1982) J. Biol.Chem. 257 (10):5333-5336.
Thomas et al., (1/1984) Proc. Nat'l. Acad. Sci. 81:357-361.
Klagsbrun (11/1980) J. Biolog. Chem. 225:10859-10864.
LaBrecque et al., (1/1982) Fed. Proc. p. 620, Abstract #2051.
Heparin-Sepharose CL-6.

Affiliated with

Also associated with

Rating

Method of purifying endothelial cell growth factors using immobi does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of purifying endothelial cell growth factors using immobi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of purifying endothelial cell growth factors using immobi will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1425776